We are not aware of any trial exploring the effect of empagliflozin on body weight in people without T2D at the time of writing
If it is, it is likely to become available first to those who need it most and will be subject to strict eligibility criteria
This development occurs as Novo Nordisk and Eli Lilly continue to defend against thousands of lawsuits claiming they failed to warn about other serious risks associated with GLP-1 drugs, including gastroparesis and vision loss
You will find the full titration schedule here, the math to calculate exact syringe units for any vial size, the hormonal considerations your prescriber may not mention, and the specific management strategies that reduce GI side effects, which hit women at roughly 2.5 times the rate they hit men on equivalent doses
Foods with significant fat content delay gastric emptying even in individuals not taking tirzepatide
On average, individuals treated with retatrutide experienced a 17.5% reduction in body weight at 24 weeks and a 24.2% reduction after 48 weeks
